Prognostic factors for disease-free survival in postoperative patients with hepatocellular carcinoma and construction of a nomogram model

Table 1 Clinicopathological characteristics of the 344 patients, n (%)

Characteristics	Median (25th–75th percentile)
Gender
Male	279 (81.10)
Female	65 (18.90)
Age (yr)
≥ 70	46 (13.37)
< 70	298 (86.63)
Smoking history
Yes	151 (43.90)
No	193 (56.10)
Alcohol consumption history
Yes	133 (38.66)
No	211 (61.34)
History of hepatitis B
Yes	86 (25.00)
No	258 (75.00)
Hypertension
Yes	80 (23.26)
No	264 (76.74)
Diabetes
Yes	41 (11.92)
No	303 (88.08)
BMI
< 18.5	26 (7.56)
≥ 18.5, < 23	160 (46.51)
≥ 23	158 (45.93)
Liver cirrhosis
Yes	256 (74.42)
No	88 (25.58)
Ascites
Yes	44 (12.79)
No	300 (87.21)
Cancer nodules
Single	299 (86.92)
Multiple	45 (13.08)
Capsule
Yes	290 (84.30)
No	54 (15.70)
Tumor diameter
≥ 5 cm	163 (47.38)
< 5 cm	181 (52.62)
Differentiation grade
Low	85 (24.71)
Moderate and High	259 (75.29)
TNM stage
I	262 (76.16)
II	38 (11.05)
III	40 (11.63)
IV	4 (1.16)
Portal vein thrombus
Yes	13 (3.78)
No	331 (96.22)
HBsAg
Positive	268 (77.91)
Negative	76 (22.09)
Surgical method
Proximal stomach	86 (25.00)
Full stomach	258 (75.00)
5-year survival
Yes	162 (47.09)
No	182 (52.91)
Prothrombin time (s)	13.80 (13.30-14.50)
Fibrinogen (g/L)	2.91 (2.41-3.54)
ALB (g/L)	40.45 (37.23-43.78)
TBIL (μmol/L)	10.00 (8.00-15.00)
TC (mmol/L)	4.35 (3.62-4.86)
ALT (U/L)	34.50 (24.00-49.00)
AST (U/L)	36.00 (27.00-52.00)
GGT (U/L)	55.50 (34.00-122.75)
NLR	2.19 (1.64-3.31)
PLR	97.67 (72.10-138.17)

BMI: Body mass index; TNM: Tumor node metastasis; HBsAg: Hepatitis B surface antigen; AFP: Alpha-fetoprotein; ALB: Albumin-bilirubin; TBIL: Total bilirubin; TC: Total cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transpeptidase; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio.